What did Fisher & Paykel Healthcare report?

• Full-year FY26 operating revenue now expected to be around $2.30 billion (previously $2.17–$2.27 billion)
• Net profit after tax (NPAT) raised to between $450 million and $470 million (previously $410 million–$460 million)
• Guidance assumes NZ:US exchange rate of 60 cents as at 31 January 2026
• Updated figures do not include any potential US tariff refunds

What else do investors need to know?

Fisher & Paykel Healthcare reported strong growth across its full range of Hospital products, contributing to the upgraded guidance. The company noted ongoing improvements in gross margin and operating margin, supported by efficiency gains and continuous improvement activities.

A major regulatory update came as the United States Supreme Court overturned tariffs imposed under the IEEPA, but Fisher & Paykel Healthcare continues to work through the refund process and potential implications. Management expects to provide a further update on any tariff impacts with the full-year results in May.

What did Fisher & Paykel Healthcare management say?

Managing Director and CEO Lewis Gradon said:

We have continued to see good growth across the full range of our Hospital products so far during our second half.

Continuous improvement activities and other efficiency gains are also contributing to improvements in our gross margin and operating margin.

What's next for Fisher & Paykel Healthcare?

Looking ahead, management will provide more detail on tariff developments and possible refunds when announcing its full-year results. The company remains confident that cost increases from tariffs will be mitigated over time by ongoing efficiency efforts.

Fisher & Paykel Healthcare continues to focus on innovation, expanding its footprint in respiratory care, and driving sustainable, profitable growth. The company maintains that the long-term strategy and direction are unchanged.

Fisher & Paykel Healthcare share price snapshot

Over the past 12 months, Fisher & Paykel shares have risen 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Fisher & Paykel Healthcare upgrades FY26 earnings outlook appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

At the time of writing, Fisher & Paykel shares were trading at $34.52 on the ASX and up 8% for the day.

The market's response was in appreciation of the broad-based strength across both the Hospital and Homecare divisions, as well as an upgrade to full-year guidance.

What did Fisher & Paykel report?

Fisher & Paykel posted operating revenue of $1.09 billion for the six months to 30 September 2025, an increase of 14% on the same period last year, or 12% in constant currency. Net profit after tax rose sharply to $213 million, up 39%, reflecting strong demand for the company's respiratory care products and the benefits of operational efficiencies.

The hospital division was the standout contributor. Revenue in this segment reached $692.2 million, up 17%, driven by broad-based strength across the consumables portfolio and a particularly strong lift in hardware sales, which grew 21% in constant currency. Notably, this momentum came despite a relatively mild respiratory season, underscoring the structural shift toward high-flow therapy and non-invasive ventilation across global hospitals.

Homecare also delivered steady growth, with revenue rising to $395.9 million, an increase of 10%. The company highlighted robust uptake of its newest obstructive sleep apnea (OSA) masks (including the Nova Nasal and Nova Micro), which are now available across several major markets. These products contributed to an 8% constant-currency lift in OSA mask revenue.

Margins improved materially during the half. Gross margin expanded to 63%, up 110 basis points year on year. Even after accounting for the drag from US tariffs on New Zealand-sourced hospital products, margin gains were supported by continuous improvement initiatives and efficiency gains across the business. Operating profit rose 31%, lifting the operating margin to 26.3%.

The board increased the interim dividend to 19 cents per share, fully imputed and payable on 16 December 2025.

Outlook

In addition to the result, FPH upgraded its full-year outlook. At prevailing exchange rates as of 31 October, the company now expects revenue of $2.17 billion to $2.27 billion (previous guidance provided in August was for revenue of $2.15billion to $2.25billion) and net profit of $410 million to $460 million (previous guidance provided in August was $390m to $440m).

Management noted that last year's Northern Hemisphere winter was unusually strong for respiratory hospitalisations. Should the upcoming season follow a similar pattern, performance is likely to land toward the higher end of guidance.

Despite the improved earnings outlook, the company emphasised that full-year margins will continue to reflect the impact of US tariffs, which are expected to reduce gross margin by around 75 basis points. Even so, Fisher & Paykel believes its operational efficiency initiatives will continue to offset part of this drag.

Foolish bottom line

Fisher & Paykel Healthcare delivered the combination of growth, margin expansion, and upgraded guidance that investors look for in a high-quality medical technology company. The strength in hospital consumables (even during a softer clinical season) suggests the company's products are becoming increasingly embedded in global care pathways. Homecare continues to provide a solid second engine of growth, supported by an expanding pipeline of OSA mask innovations.

The result reinforces FPH's long-term ambition to sustainably double its constant-currency revenue every five to six years. With clinical adoption rising, a refreshed product portfolio gaining traction, and operational efficiency improving, the market's positive reaction reflects growing confidence that the company is back on a clear upward trajectory.

The post Fisher & Paykel shares surge 8% on half-year results appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

But that was just the warm-up.

In the weeks ahead, dozens of ASX-listed companies across all sectors will deliver their outcomes for the full financial year, or for the six-month period ending in June.

And that includes some of the biggest and most closely watched ASX 200 healthcare stocks.

Kicking off proceedings was Resmed CDI (ASX: RMD) – a specialist in sleep disorder treatment – with Friday's fourth quarter and full year results.

In brief, the group's FY25 revenue jumped by 10% from a year ago, which helped to fuel a 19% increase in operating profit.

The market appeared to respond favourably, with the company's share price lifting by 1% from Thursday's close to hit record highs in Friday's trading.

ResMed's share price has now risen by 16% since the start of the year, ending last week at $42.88 per share.

In comparison, the All Ordinaries Index (ASX: XAO) is up by 5.3% over the same period.

But how will the rest of the healthcare sector perform during reporting season?

Watch this space

The list below presents 10 ASX 200 healthcare stocks set to report in August.

But before diving in, there's a few important notes to consider.

Firstly, some of these dates may change as companies conclude their number crunching.

In addition, this is not a complete list. More healthcare businesses will also be revealing their results in the coming weeks.

And one final thing.

For investors tracking other sectors, reporting dates for ten leading ASX 200 mining stocks can be found here.

Similarly, a schedule for six prominent ASX 200 energy stocks is located here.

FY25 reporting dates – ASX 200 healthcare stocks

• Thursday 14 August – Pro Medicus Ltd (ASX: PME): This imaging software provider gets the ball rolling.
• Friday 15 August – Cochlear Ltd (ASX: COH): An iconic Aussie business specialising in implantable hearing solutions.
• Tuesday 19 August – CSL Ltd (ASX: CSL): The healthcare sector's biggest company and third largest on the ASX.
• Friday 22 August – A four-company event:
  • Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH): Manufacturer of respiratory care products.
  • Healius Ltd (ASX: HLS): Diagnostic services provider.
  • Telix Pharmaceuticals Ltd (ASX: TLX): Growing diagnostic radiopharmaceuticals business.
  • Sonic Healthcare Ltd (ASX: SHL): Diversified healthcare provider.
• Monday 25 August – A double announcement:
  • Ansell Ltd (ASX: ANN): Protective personal equipment manufacturer.
  • Polynovo Ltd (ASX: PNV): Medical device developer.
• Thursday 28 August – Ramsay Health Care Ltd Fully Paid Ord. Shrs (ASX: RHC): Owner and operator of hospitals and health care clinics across 11 countries.

The post CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August appeared first on The Motley Fool Australia.

The S&P/ASX 200 Index (ASX: XJO) had a great start to the new financial year, rising 1.04% over the week to finish at 8,603 points.

Healthcare was partly propelled by a 9.73% surge for the unstoppable sector darling Pro Medicus Ltd (ASX: PME) shares.

For the first time ever, the Pro Medicus share price cracked the $300 mark last week, closing at $307.89 per share on Friday.

The stock set a new record at $316.47 on Thursday after the company announced two major contracts in the US.

Pro Medicus is now one of only two ASX 200 healthcare shares with a share price above $300.

The other is Cochlear Ltd (ASX: COH) shares.

What does Pro Medicus do?

As my colleague James explains, Pro Medicus has become a key player in the digitisation of global healthcare.

The company provides cloud-based radiology software to major hospital networks across the US, Europe, and Australia.

With high margins, zero debt, and a sticky client base, Pro Medicus continues to attract new contracts and report strong earnings growth.

Runaway momentum on Pro Medicus shares

Another colleague, Bernd, points out that we all could have invested in Pro Medicus shares for about $42 apiece just three years ago.

Let that painful truth sink in for a moment.

That is 625% share price growth.

Here is a visual aid.

In FY25, the Pro Medicus share price rose 99% to close at $285 per share on 30 June.

Pro Medicus was the second-best performer of the ASX 200 healthcare sector in FY25.

It was beaten by Sigma Healthcare Ltd (ASX: SIG) shares, which rose by 135% after the blockbuster Chemist Warehouse merger.

The S&P/ASX 200 Health Care Index (ASX: XHJ) declined in FY25, losing 6% in value.

Where to from here for Pro Medicus shares?

Morgan Stanley and Bell Potter think Pro Medicus shares don't have much more room to grow.

Morgan Stanley has an overweight rating and a 12-month price target of $310 on Pro Medicus shares.

Last week, Bell Potter downgraded Pro Medicus from a buy to a hold rating with an improved price target of $320, up from $280.

What else happened with ASX 200 healthcare shares last week?

Among the other ASX 200 healthcare sector heavyweights, CSL Ltd (ASX: CSL) shares lifted 3.59% to close at $242.76 on Friday.

Sigma shares gained 2.03% to close at $3.01 apiece.

The share price of private healthcare provider and hospital owner Ramsay Health Care Ltd (ASX: RHC) ripped 8.8% to $39.30.

The Cochlear Ltd (ASX: COH) share price rose 1.88% to $300.99.

Shares in pathology provider Sonic Healthcare Ltd (ASX: SHL) lifted 1.72% to close at $27.16 on Friday.

Resmed CDI (ASX: RMD) shares lifted 1.16% to $39.40 per share.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares lifted 0.33% to $33.82 apiece.

Among the small-cap healthcare shares, Clarity Pharmaceuticals Ltd (ASX: CU6) rose 16.67% to close at $2.94 on Friday.

ASX 200 market sector snapshot

Here's how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days:

The post Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors appeared first on The Motley Fool Australia.

During this time, the medical device company's shares have risen almost 30%.

This left them trading at $34.84 at Monday's close, which is just a fraction short of a record high.

Is it too late to invest? Let's see what Macquarie Group Ltd (ASX: MQG) is saying about the company.

What is Macquarie saying about Fisher & Paykel Healthcare?

According to a note out of the investment bank, the broker was impressed with the company's performance during FY 2025. Though, it concedes that its outlook was softer than it was expecting.

Commenting on its results, the broker said:

Hospital revenue was 2% ahead of our forecasts, driven by better-than-expected new apps revenue (+2% vs MRE, +18% CC YoY) and hardware sales (+5% vs MRE, +15% CC YoY). Management highlighted broad-based strength across the entire portfolio supported by ongoing change in clinical practice and a strong seasonal hospitalisation census. Management indicate top-end of guidance would achieve "a little bit above 12%" growth for hospital revenue, with seasonal respiratory hospitalisation rate and intensity driving demand variability (MRE ~9% CC).

Homecare revenue (+11% CC YoY) was largely in line with our forecast. Management highlighted strong contributions from new OSA masks including the Solo (launched in the US in Apr-24) and the Nova (launched in the US in Nov-24). However, CC growth declined from 14% in 1H25 to 9% in 2H25 due to competitor launches. Management expects FY26 growth to be similar to 2H25 (MRE ~8% CC).

And while it was disappointed with its guidance for FY 2026, Macquarie was pleased to see that management is guiding to better than expected margins over the medium term. It adds:

FY25 beat on top line and margin, with FY26 outlook a miss to consensus but largely in line with MRE. Despite an annualised tariff headwind of 75bps, FPH expect to achieve 65% gross margin target by FY28, ahead of our previous forecast.

Can Fisher & Paykel Healthcare shares keep rising?

The note reveals that Macquarie has retained its outperform rating on the company's shares with an improved price target of NZ$39.30. This implies potential upside of almost 13% for its NZ listed shares over the next 12 months.

Commenting on its outperform rating, the broker said:

We see the medium- to longer-term outlook as favourable, supported by uptake of new apps consumables (NHF, anaesthesia), OSA patient growth and increased utilisation from changing clinical practices.

The post Why does Macquarie think Fisher & Paykel shares are a buy? appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

According to a note out of Macquarie, its analysts have retained their outperform rating on this medical device company's shares with an improved price target of NZ$39.30 (A$36.51). This follows the release of Fisher & Paykel Healthcare's full year results last week, which beat both on the top line and with margins. And while the company's FY 2026 guidance fell short of expectations, the broker remains positive. Especially given that despite tariff headwinds, Fisher & Paykel Healthcare still expects to achieve its 65% gross margin target by FY 2028. This is ahead of what Macquarie was forecasting. Outside this, Macquarie sees the medium to longer-term outlook as favourable, supported by uptake of new app consumables, OSA patient growth, and increased utilisation from changing clinical practices. The Fisher & Paykel Healthcare share price is trading at $34.55 today.

Integral Diagnostics Ltd (ASX: IDX)

A note out of Bell Potter reveals that its analysts have retained their buy rating on this diagnostic imaging services provider's shares with an improved price target of $3.65. The broker is expecting Integral Diagnostics to deliver adjusted annual revenue growth of 34.4% to $631.2 million in FY 2025. Whereas adjusted operating EBITDA is expected to grow 35.7% to $124.2 million. The good news is that Bell Potter then expects this strong form to continue. It thinks the company is emerging with several tailwinds that could support double-digit earnings growth and ultimately a re-rating of its valuation. The Integral Diagnostics share price is fetching $2.45 at the time of writing.

Lynas Rare Earths Ltd (ASX: LYC)

Analysts at Morgan Stanley have retained their overweight rating and $10.00 price target on this rare earths producer's shares. According to the note, the broker is becoming increasingly positive on the company due to its potential to increase production thanks to the new Kalgoorlie facility. This bodes well for Lynas given its position as one of only two global rare earth supply producers outside of China. The Lynas share price is trading at $8.14 this afternoon.

The post Leading brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

ALS Ltd (ASX: ALQ)

The ALS share price is down 6% to $16.52. This has been driven by the testing services company completing a fully underwritten $350 million institutional placement this morning. According to the release, the placement was well supported and completed at a price of $16.70 per new share. This represents a 5.3% discount to its last close price. Management advised that the proceeds from the placement will be used to fund organic investment in the laboratory network. Excess funds will be used to maintain balance sheet flexibility, support future growth initiatives, and fund transaction costs.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

The Fisher & Paykel Healthcare share price is down 4% to $32.67. This morning, this medical device company released its full year results. It reported a 16% increase in total operating revenue to a record of NZ$2.02 billion. This was driven by broad-based growth in hospital consumables and double-digit growth in masks for treating obstructive sleep apnoea. Net profit after tax came in 43% higher year on year at NZ$377.2 million. While this was ahead of consensus estimates, its guidance for FY 2026 fell short of expectations.

IPD Group Ltd (ASX: IPG)

The IPD Group share price is down 8% to $3.19. This has been driven by the release of the electrical solutions provider's earnings guidance for FY 2025. IPD revealed that it expects to report EBITDA of $45.7 million to $46.3 million. This is down from its FY 2024 pro forma EBITDA of $49.8 million. IPD Group's EBIT is forecast to come in at $38.6 million to $39.2 million, which is down from $42.8 million in FY 2024.

Predictive Discovery Ltd (ASX: PDI)

The Predictive Discovery share price is down 18% to 35.5 cents. This gold miner's shares have been sold off today after it was dealt a major blow in Guinea. The company revealed that Guinea's Ministry of Mines and Geology (MMG) has announced the revocation of over 100 exploration permits. Unfortunately for Predictive Discovery, this includes the Argo and Bokoro exploration permits that it holds. It now intends to work diligently to appeal the revocations in accordance with the Mining Code.

The post Why ALS, Fisher & Paykel Healthcare, IPD, and Predictive Discovery shares are falling today appeared first on The Motley Fool Australia.

Fisher & Paykel is a New Zealand-based medical device company. It designs and manufactures life saving devices used in intensive care units and surgery theatres. The company operates in more than 120 countries and has built a strong reputation over decades.

Impressively, the company's High Flow Oxygen business has grown revenue at more than 20% per annum for the past decade. 

In the most recent half-year result, it achieved 50% profit growth, which has attracted substantial investor interest. As a result, Fisher & Paykel shares have soared 29% over the past year. They have substantially outperformed the S&P/ASX200 Index (ASX: XJO) which is up around 7%. 

Is it too late for investors to get on the bandwagon?

High barriers to entry

A major competitive advantage of Fisher & Paykel is its high barriers to entry. Its suite of High Flow oxygen devices are market leading, essential, and very difficult for competitors to replicate. 

This also gives Fisher & Paykel substantial pricing power, allowing them to raise prices without impacting demand. It is also not particularly sensitive to economic cycles, making it a relatively defensive company, which may be especially appealing to investors in the current environment.

What about tariffs?

Fisher & Paykel certainly has some exposure to tariffs. It has manufacturing plants in Mexico and New Zealand, which make up 40% and 60% of production respectively. Around 55% of its production out of Mexico is sold into the United States. 

Earlier in the year, the US announced 25% tariffs on Mexican imports. However, more recently, the US revoked its 25% tariffs on Mexican manufacturers that comply with the United States-Mexico-Canada agreement (USMCA). This includes Fisher & Paykel, which is good news for investors.

However, the company still faces a 10% tariff on products manufactured in New Zealand.

Is it a buy?

As reported by Capital Brief, UBS recently downgraded its 12 month position on Fisher & Paykel shares from 'buy' to 'neutral'. 

However, the broker raised its 12 month price target from NZ$37.3 ($34.26) to NZ$39 ($35.83).

At the time of writing, its shares are trading hands for $33.84, suggesting around 6% upside from here. 

UBS analysts believe the current share price accurately reflects a more limited tariff impact and likely strong earnings per share growth. 

While perhaps not the most compelling ASX 200 investment today, it remains a high-quality business that at least deserves a spot on any ASX investor's watchlist.

Fisher & Paykel will announce its financial results for the year ended 31 March 2025 on 28 May. This should give interested investors better insight into the company's trajectory.

The post Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result? appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

The headwinds that have dragged on global and Aussie stock markets alike since then can largely be pinned on the unpredictable and oft-changing trade policies under United States President Donald Trump.

Trump's sweeping global tariffs, in particular, have unsettled investors. This, in turn, sent many ASX All Ords stocks tumbling despite no likely fundamental changes to their long-term prospects.

"We, like almost every other investor on the planet, underestimated Trump's resolve to reshape global trade and just how far he appears willing to go to do this," said Jun Bei Liu, founder and lead portfolio manager at Ten Cap (courtesy of The Australian Financial Review).

Liu pointed to Trump's 2 April 'Liberation Day' tariff announcement as having "drastically changed the course of the macroeconomic and investment market outlook".

How should I invest in ASX All Ords stocks now?

Liu doesn't recommend buying ASX All Ords stocks based on forecasts of what Trump's next move may be.

"Pretending we can outfox Trump and know where his decisions are going, before he makes them, is not a sound investment approach," she said.

"Instead, we have tried to understand what is going on, work out the implications based on what we know and try to insulate ourselves from the chaos as best we can," she added.

Liu said she and her team at Ten Cap have instead been working to "identify and exploit mispriced opportunities".

She noted, "We were not making a call on a market rebound, but on identifying mispriced stocks based on stock specific fundamentals."

Last week (prior to Wednesday's 4.7% rebound on the All Ords), Ten Cap was buying some ASX All Ords stocks that Liu thought had fallen too far.

According to Liu:

Names we think look particularly interesting include Fisher & Paykel Healthcare Corp Ltd (ASX: FPH), Life360 Inc (ASX: 360), REA Group Ltd (ASX: REA), Pro Medicus Ltd (ASX: PME) and Cochlear Ltd (ASX: COH).

Most of those businesses have little or no tariff impact and yet most have seen their share prices fall well into double digits.

She added that medical device company Fisher & Paykel "has very strong pricing power and over time, they will increase prices and recover those costs. But the worst-case scenario is already in people's numbers".

The post 5 'particularly interesting' ASX All Ords stocks to buy amid the Trump tariff mayhem appeared first on The Motley Fool Australia.

In a new broker note, Macquarie Group Ltd (ASX: MQG) has provided investors with a deep dive into the implications of U.S. President Trump's latest round of tariffs – and it is a mixed bag for Aussie healthcare stocks.

According to the broker, while the broader healthcare sector is likely to benefit from investors seeking safety during a market selloff, the impact of tariffs on supply chains and margins is significant enough to separate the winners from the losers.

The Australian healthcare losers

Macquarie believes Ansell Ltd (ASX: ANN) is the most exposed name in its coverage, with a massive 93% of its supply chain facing U.S. reciprocal tariffs of 10% or more.

The broker notes that even assuming a 75% pass-through to customers, its earnings could drop by 17% in FY 2026 and then another 16% in FY 2027. That's a painful hit, particularly for a lower-margin business. It said:

For a low margin business, ANN's earnings face significant downside if the company cannot successfully pass through tariff increase to end customers. However, ANN's products are daily necessities for its industrial and healthcare clients who value supply chain stability over price alone.

The winners

On the other hand, ResMed Inc (ASX: RMD) and Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) look relatively well positioned.

Macquarie notes that ResMed manufactures ~40% of its products in the U.S., shielding it from some of the trade-related cost pressures. Whereas Fisher & Paykel's products, made in Mexico, are compliant under USMCA and currently avoid the steep 25% tariffs Trump has imposed on other regions.

Commenting on both companies, the broker said:

RMD remains well-placed to take on tariffs with ~40% of manufacturing completed in the US. […] A key challenge for both RMD and FPH will be negotiations with US payors to increase pricing or widening co-payments. We note upside risk for both names if respiratory devices/apparatus are exempt from tariffs under the Nairobi Protocol implemented through the Harmonised Tariff Schedule.

That said, ResMed isn't completely immune. With part of its manufacturing based in Australia and Singapore, both now facing 10% tariffs, and rising input costs from tariffed raw materials, its earnings forecasts have been trimmed by 2% for FY 2026 and FY 2027.

What about CSL and Cochlear?

Biotech giant CSL Ltd (ASX: CSL) escaped the current round of tariffs, thanks to exemptions for pharmaceutical products. However, Macquarie flagged it as a name to watch. It said:

CSL is left unscathed by reciprocal tariffs as pharmaceuticals are exempted. However, potential sector tariffs remain a key risk for CSL in the near term.

As for Cochlear Ltd (ASX: COH), it also sidestepped the tariff net, as hearing devices continue to enjoy duty-free treatment under the current U.S. harmonised tariff schedule. The broker said:

COH's hearing implants continue to be exempt from tariffs under the latest Harmonised Tariff Schedule. We think its market dominance and margins are strong defence against future tariff pressures.

Foolish takeaway

Overall, the broker is feeling a bit mixed about the tariffs. It summarises its views:

There are no clear winners from the latest round of tariffs: Exemptions insulate CSL, COH for now; FPH best positioned and ANN most impacted. We expect the rotation into high-quality, non-cyclical, large-cap healthcare names to benefit CSL, RMD, FPH, as well as domestically focused RHC. We lower estimates for RMD, FPH, ANN while awaiting tariff implementation details and updated guidance in the coming weeks.

Macquarie currently rates CSL, Fisher & Paykel, and ResMed as outperform, and Ansell and Cochlear as neutral.

The post Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare appeared first on The Motley Fool Australia.

Both companies are global leaders with strong track records, but when it comes to deciding which to buy today, the case for ResMed shares looks particularly compelling.

Fisher & Paykel

Fisher & Paykel is a New Zealand-based medical device company that designs, manufactures and markets equipment used in acute and chronic respiratory care, surgical applications, and sleep apnoea treatment.

The company has a presence in more than 120 countries and has built a strong reputation over decades. However, despite the quality of the business, analysts are taking a more measured view for now.

Morgan Stanley currently has an equal-weight (hold) rating on the stock with a $36.30 price target, compared to its recent share price of $31.40. That represents some upside, but the broker isn't quite ready to call it a buy.

ResMed Inc

ResMed, on the other hand, continues to win fans among analysts — and for good reason.

The company is the world's leading manufacturer of CPAP devices and masks for the treatment of Obstructive Sleep Apnea (OSA), a condition that is still significantly underdiagnosed. With rising awareness and greater access to sleep health services, this market is poised for long-term growth.

Goldman Sachs recently reaffirmed its conviction buy rating on ResMed shares with a $49.00 price target, well above the current share price of $33.82.

Goldman's bullish thesis rests on three pillars: Strong CPAP patient growth driven by increasing awareness of OSA. Market share gains, with ResMed already holding the #1 position globally. And margin expansion, supported by a favourable product mix and better cost efficiency.

The broker is forecasting around 10% annual revenue growth and 15% annual earnings growth through FY 2027 — a powerful combination for long-term investors.

Goldman also notes that ResMed's valuation remains attractive, with its trading multiple below its 10-year average, offering room for a potential re-rating as earnings momentum builds.

So, which one should you buy?

While Fisher & Paykel remains a high-quality healthcare business, analysts appear more cautious on its near-term outlook. ResMed, in contrast, looks well-positioned to benefit from secular growth trends, market leadership, and improving profitability — and it is trading well below its recent highs.

For investors looking for growth, value, and global exposure to a major healthcare trend, ResMed shares might just be the better pick right now.

The post Should I buy Fisher & Paykel or ResMed shares? appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

The benchmark S&P/ASX 200 Index (ASX: XJO) is up 1.05% at the time of writing, as the first week of earnings season continues on Thursday.

With dividend announcements on investors' minds, let's check out the forecast for ASX 200 healthcare dividends this year.

Dividend forecasts for ASX 200 healthcare shares

Let's take a look at the forecast 2025 dividend yields for ASX 200 healthcare shares.

In this article, we'll focus on the top 10 ASX 200 healthcare shares by market capitalisation.

The following chart shows the consensus analysts' forecasts for 2025 dividends, as published on the CommSec trading platform today.

We've calculated the dividend yields these forecasts equate to based on share prices at the time of writing.

We've also included the dividend amounts paid in 2024 so you can compare them to the 2025 predictions.

These ASX 200 healthcare shares are listed in order of market cap from largest to smallest.

So, Sonic Healthcare is expected to pay the highest dividend yield of this group in 2025.

The pathology and radiology provider will announce its 1H FY25 results and interim dividend on 20 February.

What's up with the low dividends?

As you can see, the ASX 200 healthcare sector generally does not pay high dividend yields.

In 2024, dividends made up just 1.5% of the healthcare sector's total return of 7.51%.

One reason healthcare stocks do not pay high dividends is the capital investment required to keep these businesses going.

Healthcare companies spend a lot of money on the research and development (R&D) of new medicines, technological advancements, and maintenance of expensive equipment.

This is particularly true of the ASX biotechs, such as CSL, which need a huge amount of capital to develop drugs and conduct medical trials in order to gain approval for public use.

The post Which ASX 200 healthcare share will pay the best dividend yield in 2025? appeared first on The Motley Fool Australia.